Significant Fundraising Success in UK
The Leveraged Finance Fights Melanoma (LFFM) achieved a notable milestone in its mission to combat melanoma by raising £1.4 million at its inaugural London event. This cocktail party, held at The National Gallery, drew attendance from over 600 individuals eager to make a difference for melanoma research. The funds raised will directly benefit the Melanoma Research Alliance, aiding scientists in their pursuit of innovative treatments.
Global Commitment to Cancer Research
"Our gathering celebrates the steadfast commitment of the leveraged finance and private equity sectors to advancing cancer research," stated Jeff Rowbottom, co-founder of LFFM and a board member at the Melanoma Research Alliance. He emphasized the hope this event brings to patients, survivors, and their families, facilitating the necessary resources for essential research.
Making a Transformative Impact
According to Stephanie Kauffman, president of the Melanoma Research Alliance, "The £1.4 million raised by LFFM London will significantly bolster our efforts." This financial support empowers UK-based researchers to push the frontiers of melanoma research further, striving for breakthroughs that enhance patient care worldwide.
History of the LFFM Initiative
Launched in 2011 by Brendan Dillon and Jeff Rowbottom, both melanoma survivors, LFFM has raised over £22 million since its inception. This initiative is crucial for sustaining robust funding for melanoma research and aims to generate continued awareness and mobilization around the cause.
Co-Chairs and Hosts of the Event
The London event was co-chaired by prominent figures in finance, including Roxana Mirica from Apax Partners and Sean Costello from Fitch. Their collaborative efforts made this impactful gathering possible, reflecting their dedication to advancing melanoma research.
Support from Industry Leaders
Numerous industry leaders a recognized sponsors lent their support, including Veritas Capital, Apollo, and Latham & Watkins. Their contributions not only underlined the collaborative spirit of the finance community but also the shared responsibility in addressing significant health challenges.
A Legacy of Melanoma Research Innovation
The Melanoma Research Alliance plays a pivotal role in the funding landscape since its establishment in 2007 by Debra and Leon Black. The organization is the largest non-profit entity dedicated to melanoma research worldwide. Its mission aims to eliminate suffering and fatalities caused by melanoma through the acceleration of promising scientific advancements.
Funding Impact and Efficiency
Every dollar raised for melanoma research is taken seriously, with MRA noted as one of the most fiscally efficient non-profits globally. Due to the generous support of the Black family, all operational costs are covered, allowing each donation to go directly to groundbreaking research initiatives.
Frequently Asked Questions
What was the primary goal of the LFFM event in London?
The primary goal was to raise funds to support melanoma research and expand the impact of the initiative beyond its New York origins.
Which organization benefits from the funds raised at the LFFM event?
The Melanoma Research Alliance is the primary beneficiary, funding UK-based scientists conducting critical research.
Who are some key individuals involved in LFFM?
Brendan Dillon and Jeff Rowbottom, both melanoma survivors, are the co-founders. Key event figures included Roxana Mirica and Sean Costello.
How much was raised during the LFFM London event?
The event successfully raised £1.4 million, marking a significant achievement for the cause.
What is the Melanoma Research Alliance's mission?
MRA aims to end suffering and death caused by melanoma through the support of innovative research efforts.
